AJP - Cell Physiology, Vol 260, Issue 5 C993-C999, Copyright © 1991 by American Physiological Society

ARTICLES

Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon

C. Pavoine, V. Brechler, A. Kervran, P. Blache, D. Le-Nguyen, S. Laurent, D. Bataille and F. Pecker
Institut National de la Sante et de la Recherche Medicale (INSERM) U-99, Hopital Henri Mondor, Creteil, France.

Glucagon is well known for its cardiotonic effect, but its mechanism of action remains undetermined. In the present study, we showed that glucagon, under minimal degradation conditions, had no effect on the amplitude of contractility of beating chick embryo ventricular cells. This raised the question of the contribution of the active metabolite of glucagon, glucagon-(19-29), referred to as miniglucagon, to the positive inotropic effect of glucagon. Incubation of glucagon with heart cells led to its rapid conversion into miniglucagon, as measured by radioimmunoassay. Accumulation of the metabolite was maximal after 8 min and remained stable until 15 min. reaching 6% of the initial glucagon concentration. Bacitracin inhibited this processing of glucagon into miniglucagon. Miniglucagon, from 0.1 pM to 1 nM, exerted a potent negative inotropic action. The most striking observation was a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM miniglucagon. A similar effect was obtained when glucagon was replaced by a low concentration (75 microM) of 8-bromoadenosine 3',5'-cyclic monophosphate. We conclude that glucagon processing into miniglucagon may be essential for the positive inotropic effect of glucagon on heart contraction.

This article has been cited by other articles:

				T. Uesaka, K. Yano, S. Sugimoto, and M. Ando Glucagon-like peptide isolated from the eel intestine: effects on atrial beating J. Exp. Biol., January 9, 2001; 204(17): 3019 - 3026. [Abstract] [Full Text] [PDF]

				T. A. Morinelli, J. G. Webb, A. A. Jaffa, P. J. Privitera, and H. S. Margolius A Metabolic Fragment of Bradykinin, Arg-Pro-Pro-Gly-Phe, Protects against the Deleterious Effects of Lipopolysaccharide in Rats J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 71 - 76. [Abstract] [Full Text]

				S. A. Hinke, J. A. Pospisilik, H.-U. Demuth, S. Mannhart, K. Kuhn-Wache, T. Hoffmann, E. Nishimura, R. A. Pederson, and C. H. S. McIntosh Dipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon. CHARACTERIZATION OF GLUCAGON DEGRADATION PRODUCTS AND DPIV-RESISTANT ANALOGS J. Biol. Chem., February 11, 2000; 275(6): 3827 - 3834. [Abstract] [Full Text] [PDF]

				S. Dalle, P. Smith, P. Blache, D. Le-Nguyen, L. Le Brigand, F. Bergeron, F. M. Ashcroft, and D. Bataille Miniglucagon (Glucagon 19-29), a Potent and Efficient Inhibitor of Secretagogue-induced Insulin Release through a Ca2+ Pathway J. Biol. Chem., April 16, 1999; 274(16): 10869 - 10876. [Abstract] [Full Text] [PDF]

				A. Sauvadet, T. Rohn, F. Pecker, and C. Pavoine Arachidonic Acid Drives Mini-glucagon Action in Cardiac Cells J. Biol. Chem., May 9, 1997; 272(19): 12437 - 12445. [Abstract] [Full Text] [PDF]

				A. Sauvadet, T. Rohn, F. Pecker, and C. Pavoine Synergistic Actions of Glucagon and Miniglucagon on Ca2+ Mobilization in Cardiac Cells Circ. Res., January 1, 1996; 78(1): 102 - 109. [Abstract] [Full Text]